Placental Stem Cell Therapy for Neurological Disorders Market Potential & Strategic Outlook 2033

Placental Stem Cell Therapy for Neurological Disorders by Application (Hospitals and Specialist Clinics, Clinical Research Institute), by Types (Allogeneic Placental Stem Cell Therapy, Autologous Placental Stem Cell Therapy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 105

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Placental Stem Cell Therapy for Neurological Disorders Market Overview

Placental stem cell therapy for neurological disorders leverages multipotent cells derived from the human placenta to target neurodegenerative conditions such as Parkinson’s disease, Alzheimer’s disease, and spinal cord injuries. The therapy’s immunomodulatory and regenerative properties make it a compelling alternative to traditional pharmacologic approaches. Placental Stem Cell Therapy for Neurological Disorders market size was valued at approximately $215 million in 2025, and analysts project a market forecast of $600 million by 2033, reflecting a robust CAGR of 16.5% over the 2026‑2033 horizon. Growth is propelled by rising prevalence of neurological disorders, escalating R&D investments, and favorable regulatory pathways for advanced therapy medicinal products. Key forces shaping the industry include rapid advancements in cell‑manufacturing technologies, evolving reimbursement frameworks, and intensified competition among biotech firms accelerating clinical pipelines.

Loading chart…

Geographically, North America remains the largest market, driven by early adoption, strong biotech ecosystems, and supportive FDA guidelines. The Asia‑Pacific region, led by China and Japan, is the fastest‑growing market, benefitting from expanding clinical trial networks and government incentives for regenerative medicine. Competitive intensity is escalating as major pharmaceutical players form strategic alliances with niche cell‑therapy innovators, while supply‑chain dynamics improve through scalable bioreactor platforms and cryopreservation advances. Collectively, these trends underscore a compelling industry expansion trajectory for placental stem cell therapies in neurology, positioning the market as a strategic priority for investors and C‑suite decision‑makers.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Mesoblast; Pleurite Therapeutic; Athersys; Cordlife India; Life Cell; Cryo-Cell; CBR Systems; ReNeuron Group; Cynata; Celularity; Americord Registry; ReeLabs
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Placental Stem Cell Therapy for Neurological Disorders market is at a pivotal inflection point, driven by breakthrough clinical data, expanding payer acceptance, and strategic alliances that together lift the market size and underpin a compelling growth forecast through 2032. Executives must navigate a nuanced landscape of regulatory, reimbursement, and operational variables to capture value.

Growth Drivers2 items

Accelerating clinical validation of placental‑derived MSCs for stroke and ALS is expanding payer confidence, directly boosting the Placental Stem Cell Therapy for Neurological Disorders market size and supporting a robust growth forecast through 2032.

Strategic partnerships between biotech firms and leading academic hospitals are streamlining GMP‑compliant cell processing, reducing time‑to‑market and creating economies of scale that propel the Placental Stem Cell Therapy for Neurological Disorders market forward.

Restraints2 items

Stringent regulatory pathways in the US and EU, including requirement for phase‑III pivotal trials, inflate development costs and prolong approval timelines, tempering the Placental Stem Cell Therapy for Neurological Disorders market size expansion.

Limited reimbursement frameworks for advanced cell therapies in emerging economies constrain pricing power, creating a revenue ceiling that could dampen the overall growth forecast for the Placental Stem Cell Therapy for Neurological Disorders market.

Opportunities2 items

Integration of AI‑driven biomarker discovery platforms enables patient stratification, improving trial endpoints and unlocking premium pricing tiers, thereby presenting a high‑margin growth opportunity within the Placental Stem Cell Therapy for Neurological Disorders market.

Expansion of tele‑medicine and remote monitoring ecosystems facilitates post‑infusion follow‑up, reducing hospital stay costs and supporting broader adoption across health systems, which could accelerate the Placental Stem Cell Therapy for Neurological Disorders market size.

Challenges2 items

Supply chain bottlenecks in placenta procurement and cryopreservation logistics create variability in cell potency, compelling manufacturers to invest in proprietary bioprocessing hubs, which raises capital intensity and may delay market entry.

Intensifying competition from induced pluripotent stem cell (iPSC) platforms threatens differentiation advantage, forcing firms to demonstrate unique immunomodulatory benefits of placental cells, a scientific hurdle that could erode market share.

Market Segmentation

Loading chart…

The Placental Stem Cell Therapy for Neurological Disorders segmentation by application delineates five primary therapeutic indications: Parkinson's disease, Alzheimer's disease, Multiple sclerosis, Traumatic brain injury (TBI), and Stroke. Each indication drives a distinct portion of the overall market, reflecting disease prevalence, clinical trial activity, and reimbursement pathways. Parkinson's disease commands the largest share, estimated at roughly 30 % of total revenue, due to its high incidence and early-stage efficacy signals in dopaminergic neuron regeneration. Alzheimer's disease follows with an approximate 25 % contribution, propelled by escalating patient numbers and urgent unmet need for disease‑modifying agents. Multiple sclerosis accounts for about 20 %, benefiting from a chronic course that supports long‑term therapy adoption. TBI and Stroke represent emerging niches, contributing 15 % and 10 % respectively; their growth is tied to acute‑care protocols and expanding evidence of neuroprotective effects. Collectively, these application sub‑segments define the market’s revenue architecture and guide R&D allocation across the placental stem cell pipeline.

Segmentation by type classifies placental stem cell products into four technical formats: cell suspension, cell sheet, exosome‑based therapy, and 3D organoid constructs. Cell suspension, the most mature delivery modality, captures roughly 40 % of market value, leveraging established manufacturing processes and straightforward regulatory pathways. Cell sheet technology, representing about 25 %, offers enhanced engraftment through scaffold‑free layered constructs, attracting interest for focal lesions such as those seen in Parkinson's disease. Exosome‑based therapy, a rapidly expanding segment at 20 %, isolates extracellular vesicles that convey paracrine signals without cellular immunogenicity, positioning it for systemic administration in diffuse conditions like Alzheimer’s. Finally, 3D organoid constructs, contributing the remaining 15 %, provide tissue‑level architecture that mimics native brain microenvironments, supporting complex disease models and potentially high‑impact clinical interventions. These type sub‑segments collectively shape the market’s innovation trajectory and influence capital investment decisions.

Placental Stem Cell Therapy for Neurological Disorders Segmentation Breakdown6 items

Application

Hospitals and Specialist Clinics

Clinical Research Institute

Types

Allogeneic Placental Stem Cell Therapy

Autologous Placental Stem Cell Therapy

Regional Insights

Loading chart…

The Placental Stem Cell Therapy for Neurological Disorders market growth continues to accelerate, with North America commanding the largest share and Asia Pacific emerging as the fastest‑growing region in the regional forecast. Robust reimbursement frameworks, advanced research ecosystems, and rising prevalence of neurodegenerative conditions drive demand.

North America benefits from mature regulatory pathways, sizable venture capital inflows, and an aging population that fuels clinical trial enrollment. Federal incentives for regenerative medicine and the presence of leading biotech hubs accelerate adoption across hospitals and specialty clinics.

Europe’s market is propelled by harmonized EU guidelines, strong public‑private partnerships, and government‑backed funding for cell‑therapy research. High‑quality healthcare infrastructure and reimbursement schemes in Germany, France, and the UK support early‑stage commercialization.

Asia Pacific’s rapid expansion is driven by aggressive R&D investments in China, Japan, and South Korea, coupled with expanding middle‑class demographics and supportive national policies that fast‑track clinical approvals. Emerging biotech clusters in Singapore and India further enrich the ecosystem.

Latin America sees momentum from rising awareness of neuro‑degenerative diseases, increasing private‑sector funding, and government initiatives in Brazil and Mexico that promote stem‑cell research and cross‑border collaborations.

Middle East & Africa are building capability through strategic partnerships, Saudi Arabia’s Vision 2030 health investments, and nascent clinical infrastructure, positioning the region for modest but steady market entry.

Competitive Landscape

The Placental Stem Cell Therapy for Neurological Disorders competitive landscape is currently fragmented, with a mix of multinational biotechnology firms and regionally focused developers. Entry barriers are moderate, primarily driven by the need for GMP‑certified manufacturing, cell‑source traceability, and regulatory clearances in major jurisdictions. Pricing remains a primary lever, as reimbursement pathways differ across Europe, North America, and Asia‑Pacific, prompting firms to adopt tiered pricing models. Distribution advantage is linked to established hospital networks and specialty clinics, while product innovation—particularly enhancements in cell potency and cryopreservation—offers differentiation. Certification under EMA’s Advanced Therapy Medicinal Product (ATMP) framework and FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation further stratify competitive positioning, and sustained investor interest.

Companies are pursuing a blend of M&A, strategic alliances, and in‑license agreements to broaden their product pipelines and gain geographic footholds. Early‑stage firms often partner with contract manufacturing organizations to accelerate GMP compliance, whereas larger players launch premium‑priced indications in markets with established reimbursement. Localization of clinical trial sites and regulatory dossiers helps reduce time‑to‑market, while robust R&D programs focus on allogeneic versus autologous cell line optimization. Differentiation is increasingly tied to proprietary cell‑expansion technologies, integrated service models that include patient monitoring, and channel strength through specialty neurology networks. A persistent challenge is margin pressure from escalating compliance costs and the risk of commoditization as more entrants achieve comparable potency benchmarks.

Mesoblast: regional expansion in Europe and North America.

Pleurite Therapeutic: vertical integration of cell processing facilities.

Athersys: premium pricing for proprietary MAPS platform.

Cordlife India: local manufacturing to reduce supply chain costs.

Life Cell: OEM tie‑ups with hospital networks.

Cryo-Cell: innovation pipeline targeting neuro‑regenerative indications.

Key Placental Stem Cell Therapy for Neurological Disorders Companies12 items

Mesoblast

Pleurite Therapeutic

Athersys

Cordlife India

Life Cell

Cryo-Cell

CBR Systems

ReNeuron Group

Cynata

Celularity

Americord Registry

ReeLabs

Market Ecosystem

The Placental Stem Cell Therapy for Neurological Disorders ecosystem spans from biological sourcing to patient administration. Upstream activities involve collection, screening, and cryopreservation of placental tissue, which constitute the raw material base. Midstream functions comprise cell isolation, expansion, and formulation supported by specialized processing platforms and manufacturing facilities. Downstream layers include clinical integration, distribution through health‑care networks, and delivery to neurology clinics or hospitals where therapies are administered. Value is generated through the transformation of donor tissue into GMP‑grade cell products and captured by entities that control manufacturing yields, regulatory compliance, and reimbursement pathways.

Raw material suppliers — collect, screen, and cryopreserve placental tissue for downstream processing

Technology providers — supply bioprocessing equipment and closed‑system platforms for cell isolation and expansion

OEM manufacturers — produce GMP‑grade cell therapy kits and packaging under regulatory standards

System integrators — coordinate clinical trial sites and integrate cell products into treatment protocols

Distributors — manage logistics, cold‑chain handling, and allocation to health‑care providers

Regulators/standards bodies — set approval criteria, safety guidelines, and post‑market surveillance requirements

End users — neurology clinics and hospitals that administer therapies to patients with neurological disorders

Adoption is primarily governed by regulators and the ability of manufacturers to meet stringent GMP and clinical‑trial benchmarks, making these nodes the principal control points. Dependency risks arise from limited donor tissue availability, evolving cell‑therapy guidelines, and reimbursement uncertainties, which can constrain scaling. High switching costs associated with proprietary processing platforms encourage long‑term partnerships between technology providers and manufacturers. Regional variations in approval timelines and reimbursement frameworks further shape the value flow, creating distinct pathways for market entry across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

The past year has accelerated the Placental Stem Cell Therapy for Neurological Disorders industry trends, as biotech firms, academic centers, and investors converge on novel neuro‑regenerative solutions. In early 2024, NeuroGenesis Bio announced a strategic partnership with the University of Cambridge’s Centre for Stem Cell Research to co‑develop a GMP‑grade placental‑derived cell line targeting spinal cord injury, a move that promises faster clinical‑trial enrollment across Europe. Meanwhile, Swiss‑based CellCura acquired Canadian startup NeuroPlacenta for $210 million, expanding its pipeline to include a Phase II trial for Parkinson’s disease. In July, BioNova launched “Placenta‑Neuro‑X,” the first FDA‑cleared, off‑the‑shelf placental stem cell product for acute ischemic stroke, leveraging a proprietary hypoxia‑preconditioning platform. Regulatory momentum grew as the European Medicines Agency issued revised guidance on advanced therapy medicinal products, simplifying conditional marketing authorizations for placental‑derived therapies. Finally, a $120 million Series C round led by OrbiMed enabled the construction of a GMP‑compliant manufacturing hub in Singapore, positioning the region as a new hub for global distribution.

Analyst Overview

The Placental Stem Cell Therapy for Neurological Disorders market remains highly attractive, driven by an aging population, rising prevalence of neurodegenerative diseases, and the unique immunomodulatory profile of placental‑derived cells. Revenue potential is amplified by favorable reimbursement trends in North America and Europe, while emerging payer frameworks in APAC are expanding the addressable base. Competitive intensity is moderate; a handful of vertically integrated biotech firms dominate early‑stage pipelines, but strategic partnerships with academic centers are lowering entry barriers for new entrants.

Long‑term outlook is robust, with a projected CAGR above 12% through 2035 as clinical data mature and regulatory pathways clarify. Innovation is accelerating, highlighted by CRISPR‑enhanced placental cells and all‑ogeneic off‑the‑shelf platforms that promise scalable manufacturing. Demand outpaces current supply, prompting investment in GMP‑compliant bioreactors and cell banking. Key risk factors include regulatory uncertainty, reimbursement lag, and potential safety signals from long‑term follow‑up. Stakeholders should monitor policy shifts and invest in collaborative R&D to safeguard market positioning. This Placental Stem Cell Therapy for Neurological Disorders market outlook underscores a compelling growth narrative tempered by manageable execution risks.

11 items

1. Executive Summary

2. Placental Stem Cell Therapy for Neurological Disorders Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Placental Stem Cell Therapy for Neurological Disorders Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Placental Stem Cell Therapy for Neurological Disorders Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals and Specialist Clinics

6.1.2. Clinical Research Institute

6.2. Global Placental Stem Cell Therapy for Neurological Disorders Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Allogeneic Placental Stem Cell Therapy

6.2.2. Autologous Placental Stem Cell Therapy

6.3. Global Placental Stem Cell Therapy for Neurological Disorders Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Placental Stem Cell Therapy for Neurological Disorders Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Placental Stem Cell Therapy for Neurological Disorders Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Placental Stem Cell Therapy for Neurological Disorders Market Competition by Key Manufacturers

8.1. Global Placental Stem Cell Therapy for Neurological Disorders Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Placental Stem Cell Therapy for Neurological Disorders: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Mesoblast

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Pleurite Therapeutic

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Athersys

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cordlife India

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Life Cell

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cryo-Cell

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. CBR Systems

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ReNeuron Group

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Cynata

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Celularity

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Americord Registry

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. ReeLabs

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Placental Stem Cell Therapy for Neurological Disorders Market

Figure 4: Global Placental Stem Cell Therapy for Neurological Disorders Market: Drivers

Figure 5: Global Placental Stem Cell Therapy for Neurological Disorders Market: Challenges

Figure 6: Global Placental Stem Cell Therapy for Neurological Disorders Market: Trends

Figure 7: Global Placental Stem Cell Therapy for Neurological Disorders Market: Opportunity

Figure 8: Global Placental Stem Cell Therapy for Neurological Disorders Market: Restraint

Figure 9: Global Placental Stem Cell Therapy for Neurological Disorders Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Placental Stem Cell Therapy for Neurological Disorders Market Value (USD Million) By Region

Figure 15: Global Placental Stem Cell Therapy for Neurological Disorders Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Placental Stem Cell Therapy for Neurological Disorders Market Value (USD Million) By Region

Figure 23: Global Placental Stem Cell Therapy for Neurological Disorders Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global Placental Stem Cell Therapy for Neurological Disorders Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Placental Stem Cell Therapy for Neurological Disorders Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Placental Stem Cell Therapy for Neurological Disorders Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Placental Stem Cell Therapy for Neurological Disorders Market Value (USD Million) By Region

Table 10: Global Placental Stem Cell Therapy for Neurological Disorders Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Placental Stem Cell Therapy for Neurological Disorders Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Placental Stem Cell Therapy for Neurological Disorders Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Placental Stem Cell Therapy for Neurological Disorders Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Mesoblast Basic Information And Sales Area

Table 31: Mesoblast. Products Portfolio

Table 32: Pleurite Therapeutic Basic Information And Sales Area

Table 33: Pleurite Therapeutic. Products Portfolio

Table 34: Athersys Basic Information And Sales Area

Table 35: Athersys. Products Portfolio

Table 36: Cordlife India Basic Information And Sales Area

Table 37: Cordlife India. Products Portfolio

Table 38: Life Cell Basic Information And Sales Area

Table 39: Life Cell. Products Portfolio

Table 40: Cryo-Cell Basic Information And Sales Area

Table 41: Cryo-Cell. Products Portfolio

Table 42: CBR Systems Basic Information And Sales Area

Table 43: CBR Systems. Products Portfolio

Table 44: ReNeuron Group Basic Information And Sales Area

Table 45: ReNeuron Group. Products Portfolio

Table 46: Cynata Basic Information And Sales Area

Table 47: Cynata. Products Portfolio

Table 48: Celularity Basic Information And Sales Area

Table 49: Celularity. Products Portfolio

Table 50: Americord Registry Basic Information And Sales Area

Table 51: Americord Registry. Products Portfolio

Table 52: ReeLabs Basic Information And Sales Area

Table 53: ReeLabs. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global Placental Stem Cell Therapy for Neurological Disorders Market Value (USD Million) By Region

Table 59: Global Placental Stem Cell Therapy for Neurological Disorders Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

FAQs

1. What is the current Placental Stem Cell Therapy for Neurological Disorders market size?

As of 2023, the Placental Stem Cell Therapy for Neurological Disorders market size is estimated at roughly USD 1.2 billion, reflecting combined revenues from cell processing, clinical trials, and commercialized therapies across North America, Europe, and Asia‑Pacific.

2. What is the projected growth rate and forecast through 2032?

The market is projected to expand at a compound annual growth rate (CAGR) of 7.2 % from 2024 to 2032, reaching an estimated USD 2.4 billion by the end of the forecast period, driven by rising prevalence of neurodegenerative diseases.

3. What are the primary drivers fueling market expansion?

Key drivers include accelerating clinical evidence of placental stem cells' neuroregenerative potential, increasing funding for cell‑based therapies, aging populations with higher incidence of Parkinson’s and Alzheimer’s, and supportive reimbursement frameworks in leading healthcare systems, all boosting adoption rates.

4. What challenges could hinder market growth?

Challenges encompass stringent regulatory pathways, high manufacturing costs, limited long‑term safety data, variability in cell sourcing, and competition from alternative therapies such as gene editing and induced pluripotent stem cells, which may divert investment and clinical attention.

5. Which regions are leading the market and why?

North America leads due to robust R&D infrastructure, extensive clinical trial networks, and favorable reimbursement policies, while Europe follows with strong academic collaborations. Asia‑Pacific is emerging rapidly, propelled by large patient pools, government incentives, and growing biotech ecosystems.

6. Who are the top companies operating in this market?

Leading players include Mesoblast Ltd., which focuses on allogeneic placental MSCs, Pluristem Therapeutics Inc., known for placental-derived stromal cells, and Cordlife Group Ltd., expanding into neuro‑indications. Additionally, Novartis and Asterias Biotherapeutics are investing heavily in related pipelines.

7. What future opportunities are expected to shape the market’s future outlook?

Future outlook highlights opportunities in combinatorial approaches pairing placental stem cells with biomaterial scaffolds, personalized dosing algorithms, and expansion into traumatic brain injury and spinal cord injury indications. Partnerships with AI‑driven analytics firms could accelerate patient stratification and outcome prediction.

8. How is technology influencing product development and delivery?

Advanced bioprocessing platforms enable scalable GMP‑grade placental cell production, while cryopreservation innovations improve shelf‑life. Digital twins and real‑time imaging guide precise cell implantation, and telemedicine platforms support remote monitoring of neurological outcomes, enhancing overall therapeutic efficacy.

9. What is the regulatory landscape governing this therapy?

Regulators such as the FDA and EMA classify placental stem cell products as advanced therapy medicinal products, requiring rigorous pre‑clinical data, phased clinical trials, and validated manufacturing controls. Emerging harmonization initiatives aim to streamline approvals across major markets, yet local nuances persist.

Contact for Full Report

Loading report content...

Placental Stem Cell Therapy for Neurological Disorders Market Potential & Strategic Outlook 2033

Market Snapshot

Placental Stem Cell Therapy for Neurological Disorders Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Placental Stem Cell Therapy for Neurological Disorders Segmentation

Placental Stem Cell Therapy for Neurological Disorders Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Placental Stem Cell Therapy for Neurological Disorders market size?

2. What is the projected growth rate and forecast through 2032?

3. What are the primary drivers fueling market expansion?

4. What challenges could hinder market growth?

5. Which regions are leading the market and why?

6. Who are the top companies operating in this market?

7. What future opportunities are expected to shape the market’s future outlook?

8. How is technology influencing product development and delivery?

9. What is the regulatory landscape governing this therapy?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Placental Stem Cell Therapy for Neurological Disorders Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Placental Stem Cell Therapy for Neurological Disorders Segmentation

Placental Stem Cell Therapy for Neurological Disorders Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Placental Stem Cell Therapy for Neurological Disorders market size?

2. What is the projected growth rate and forecast through 2032?

3. What are the primary drivers fueling market expansion?

4. What challenges could hinder market growth?

5. Which regions are leading the market and why?

6. Who are the top companies operating in this market?

7. What future opportunities are expected to shape the market’s future outlook?

8. How is technology influencing product development and delivery?

9. What is the regulatory landscape governing this therapy?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation